GlassScriptPhysician profile
Christopher J Lynn
NPI 1922479617
$6,440.85
in general payments reported to CMS, 2019-2025
21 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,405 · 2022: $1,440 · 2023: $1,118 · 2024: $1,171 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,259.08 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $759.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $512.78 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $470.13 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $364.04 | 2021-2024 | Caplyta |
| Alkermes, INC. | $345.62 | 2021-2025 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $229.07 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $218.40 | 2021-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $216.77 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $207.91 | 2021-2022 | |
| Lundbeck LLC | $176.01 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $170.31 | 2021-2022 | |
| Brainsway USA INC | $161.46 | 2023-2024 | Brainsway Deep Tms System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.32 | 2024 | Rejoyn |
| Axsome Therapeutics, INC. | $54.99 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $53.36 | 2021-2022 | |
| Neuronetics, INC. | $44.44 | 2022-2023 | Neurostar Tms Therapy System |
| Uswm, LLC | $43.99 | 2022 | |
| Avanir Pharmaceuticals, INC. | $23.84 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.90 | 2025 | Qelbree |
| Corium, LLC | $22.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.